RELX NV (RENX)

21.19
0.58 2.66
NYSE : Commercial Services
Prev Close 21.77
Open 21.49
Day Low/High 21.18 / 21.55
52 Wk Low/High 20.06 / 23.30
Volume 547.93K
Avg Volume 84.90K
Exchange NYSE
Shares Outstanding 1.05B
Market Cap 21.72B
EPS 1.10
P/E Ratio 9.06
Div & Yield 0.45 (2.08%)

Latest News

RenalytixAI Releases Positive Interim Results In Expanded Validation Study For KidneyIntelX™

RenalytixAI Releases Positive Interim Results In Expanded Validation Study For KidneyIntelX™

Data development plan review continues with FDA under Breakthrough Device designation process; Performance meets or exceeds targets for identifying rapid kidney function decline in patients with Type 2 diabetes and existing chronic kidney disease

U.S. CPT® Code Granted For KidneyIntelX™

U.S. CPT® Code Granted For KidneyIntelX™

CPT Code a key component for reimbursement from private medical insurance and Medicare

Study Published In Journal Of Clinical Investigation Insight Demonstrates Ability To Predict Early Rejection In Kidney Transplant With FractalDx Portfolio Technology

Study Published In Journal Of Clinical Investigation Insight Demonstrates Ability To Predict Early Rejection In Kidney Transplant With FractalDx Portfolio Technology

Positive study results support successful development of a predictive blood test for transplant patients to meet critical unmet medical need

RenalytixAI Expands Core Investigator Group For Kidney Transplant Advanced Diagnostic Program

RenalytixAI Expands Core Investigator Group For Kidney Transplant Advanced Diagnostic Program

Investigators now include transplant experts from University of Oxford, Yale School of Medicine, Emory University School of Medicine, Icahn School of Medicine at Mount Sinai, University of Manitoba, Westmead Hospital Sydney, University of Alabama at Birmingham, and Cleveland Clinic

RenalytixAI And University Medical Center Groningen To Evaluate KidneyIntelX™ For Early Identification And Guiding Therapeutic Treatment Of Diabetic Kidney Disease

RenalytixAI And University Medical Center Groningen To Evaluate KidneyIntelX™ For Early Identification And Guiding Therapeutic Treatment Of Diabetic Kidney Disease

NEW YORK, May 7, 2019 /PRNewswire/ -- Renalytix AI plc (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today a collaboration with University Medical Center Groningen (UMCG), Netherlands, to...

FDA Grants Breakthrough Device Designation To KidneyIntelX™

FDA Grants Breakthrough Device Designation To KidneyIntelX™

Provides Priority Regulatory Review of AI-Enabled Diagnostic for Fast-Progressing Kidney Disease

RELX Enters Oversold Territory

RELX Enters Oversold Territory

The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. RELX NV presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors.